ChinaBio® Partnering Forum 2017: ConSynance tests waters in China with differentiated NASH asset

Dr. Shuang Liu, president and co-founder of upstate New York-based ConSynance Therapeutics discusses with Scrip’s Brian Yang the startup's plan to develop and commercialize its multiple assets in various stages.
Armed with years of experience developing assets working at Albany Medical Research Inc. for big pharma like BMS, Shuang Liu and her business partner struck out on their own and founded ConSynance.
Now they have multiple assets in different stages, targeting NASH, fibrosis, central nerve system (CNS), diabetes and irritable bowel syndrome.
The company also collaborates with Albany Medical College for diabetes and obesity treatment, and owns the rights to a novel treatment for IBS targeting 5-HT3 receptor.
This interview was recorded at ChinaBio® Partnering Forum organized by EBD Group and ChinaBio® Group in Zhuhai, Guangdong, in May 2017.